KURA
$8.58
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer.
Recent News
Implied Volatility Surging for Kura Oncology Stock Options
Investors need to pay close attention to Kura Oncology stock based on the movements in the options market lately.
How The Kura Oncology (KURA) Story Is Shifting With Komzifti And New Street Targets
Kura Oncology’s fair value estimate has been adjusted slightly, with the price target moving from US$33.00 to US$32.45. This tweak reflects a mix of upbeat and cautious Street views as analysts react to Komzifti’s early launch feedback, Q4 updates, and management guidance that have led to both higher and lower targets across the range. As you read on, you will see how these shifting targets fit into the broader analyst narrative and what to watch to stay on top of the story. Stay updated as...
Kura Oncology Q4 Earnings Call Highlights
Kura Oncology (NASDAQ:KURA) executives used the company’s fourth-quarter and fiscal 2025 earnings call to highlight what CEO Troy Wilson called a “defining year,” driven by the FDA approval of Komzifti and the start of its U.S. commercial launch. Management said early prescription trends and market
Kura Oncology Inc (KURA) Q4 2025 Earnings Call Highlights: KOMZIFTI Launch Boosts Revenue Amid ...
Kura Oncology Inc (KURA) reports a successful launch of KOMZIFTI with strong revenue growth, despite increased R&D and administrative costs.
Kura Oncology, Inc. Q4 2025 Earnings Call Summary
Moby summary of Kura Oncology, Inc.'s Q4 2025 earnings call